Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We thus suggest that developing a new combination regimen of gamabufotalin plus a p38 MAPK inhibitor and/or inhibitors for VEGF/VEGFR could improve the efficacy of the drug, and may provide more therapeutic benefits to patients with glioblastoma.
|
31610157 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that AURKA and KDR genes are hub driver genes in glioblastoma with bioinformatics technology including WGCNA analysis, PPI network, GO, KEGG analysis and GSEA analysis.
|
31706255 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.
|
30718358 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab resistance of VEGFR2-expressing glioblastoma cells prompted interrogation of autocrine VEGF-C/VEGFR2 signaling in glioblastoma.
|
29939339 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VGB bound to both VEGFR1 and VEGFR2 in human umbilical vein endothelial cells (HUVECs) and 4 T1 mammary carcinoma tumor (MCT) cells, and inhibited the proliferation of HUVE, 4 T1 MCT, and U87 glioblastoma cells.
|
30251659 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
[<sup>111</sup>In]In-NODAGA-Z<sub>VEGFR2</sub>-Bp<sub>2</sub> appears to be a promising probe for in vivo noninvasive visualization of tumor angiogenesis in glioblastoma.
|
30214632 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
|
29599413 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the MET-addicted glioblastoma model E98, yet did not prevent development of recurrent and cabozantinib-resistant tumors.
|
28751462 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we analyzed the effect of AG1433 (a PDGFR inhibitor), SU1498 (a VEGFR inhibitor) and BEZ235 (a PI3K/Akt/mTOR signaling pathways inhibitor) on glioblastoma cells in vitro.
|
26339347 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF signaling through VEGFR-2 is the major factor in glioblastoma angiogenesis.
|
25388940 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
|
25682871 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
|
25676691 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present work, we propose the use of uniform mesoporous silica nanoparticles (MSNs) for VEGFR targeted positron emission tomography imaging and delivery of the anti-VEGFR drug (i.e., sunitinib) in human glioblastoma (U87MG) bearing murine models.
|
25353068 |
2014 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore a potential role of Flk-1 in the vasculogenesis, we investigated two glioblastoma cell lines U87 and GSDC, both of which express Flk-1 and exhibit a vascular phenotype on Matrigel.
|
22654102 |
2012 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant difference was observed in the frequency of amplification of these genes in primary and secondary glioblastomas or in glioblastomas with and without IDH1 mutations, suggesting that amplification of PDGFRA, KIT and KDR may be implicated in the pathogenesis of a small fraction of both subtypes of glioblastoma.
|
21382095 |
2011 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, this study provides little evidence that VEGF and VEGFR2 polymorphisms are important for glioblastoma survival.
|
21191630 |
2011 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The molecular biology of adult malignant glioma is now well described and targeted therapies against VEGFR are already playing a role in the management of glioblastoma.
|
19637006 |
2009 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that KDR mRNA is co-expressed with flt-1 in vascular cells in glioblastoma but not in low-grade glioma.
|
7525492 |
1994 |